RedHill Biopharma (RDHL) Long-Term Investments (2025)
RedHill Biopharma's (RDHL) quarterly Long-Term Investments came in at $12.0 million in Q4 2025.
RedHill Biopharma (RDHL) Long-Term Investments (2025) Analysis & Trends
RedHill Biopharma (RDHL) has 1 years of Long-Term Investments data on file, last reported at $12.0 million in Q4 2025.
- On a quarterly basis, Long-Term Investments changed N/A year-over-year to $12.0 million in Q4 2025; TTM through Dec 2025 was $12.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $12.0 million, changed N/A from the prior year.
- Long-Term Investments for Q4 2025 stood at $12.0 million.
- Over the last five years, Long-Term Investments for RDHL reached as high as $12.0 million in Q4 2025 and fell as low as $12.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 56.09 Mn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 1.32 Bn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | 12.05 Mn |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 146.10 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | - |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | 6.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 12.05 Mn |